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Abstract: Soy isoflavones are phytoestrogens with potential hormonal activity due to their 
similar chemical structure to 17-β-estradiol. The increasing availability of soy isoflavones 
throughout  the  food  supply  and  through  use  of  supplements  has  prompted  extensive 
research  on  biological  benefits  to  humans  in  chronic  disease  prevention  and  health 
maintenance. While much of this research has focused on adult populations, infants fed soy 
protein based infant formulas are exposed to substantial levels of soy isoflavones, even 
when compared to adult populations that consume a higher quantity of soy-based foods. 
Infant exposure, through soy formula, primarily occurs from birth to one year of life, a 
stage  of  development  that  is  particularly  sensitive  to  dietary  and  environmental 
compounds.  This  has  led  investigators  to  study  the  potential  hormonal  effects  of  soy 
isoflavones on later reproductive health outcomes. Such studies have included minimal 
human data with the large majority of studies using animal models. This review discusses 
key aspects of the current human and animal studies and identifies critical areas to be 
investigated as there is no clear consensus in this research field.  
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1. Introduction  
Soy protein based infant formula (SBIF) has been used throughout the world for over 100 years [1]. 
SBIFs  were  initially  developed  as  an  alternative  to  cow’s  milk  based  formula  for  infants  with 
immunoglobulin  E-mediated  milk  allergies,  post-infectious  diarrhea  due  to  lactose  intolerance, 
galactosemia, or for infants who required a vegan substitute [1]. SBIFs were originally prepared from 
soy flour which had lower digestibility and lower protein content compared to the soy protein isolate 
(SPI) which is used currently [2]. SBIF have been further modified to include methionine, iodine, 
carnitine, taurine, choline and inositol [1]. According to the Infant Formula Act of 1980, amended in 
1986, SBIFs meet all nutritional requirements for term infants [3]. Data from North America suggest 
that approximately 37.2% to 43.8% of infants are formula fed three to six months postpartum [4]. 
Recent  data  suggests  the  prevalence  of  feeding  SBIF  is  20–25%  in  Canada  [5]  and  the  United 
States [6] and markedly lower (2–3%) in the United Kingdom [7] and Australia [8]. 
1.1. Isoflavones in Soy Protein Based Infant Formulas (SBIF) 
SBIFs represent a significant source of soy isoflavones with potential hormone-like activities [9] as 
they contain a diphenolic ring that allows them to bind to the estrogen receptor (ER) [10]. There are 
two  predominant  types  of  soy  isoflavones,  daidzein  and  genistein,  which  preferentially  bind  to 
ER- [11].  In  addition  to  exerting  hormone-like  effects,  isoflavones  may  also  act  through  a 
non-hormonal  mechanism  by  inhibiting  tyrosine  kinases  and  inducing  some  growth  arrest  and 
apoptosis [12]. 
Although soy isoflavones are weakly estrogenic, approximately 10
2 to 10
3 fold less potent than 
endogenous  estrogen  [13],  infants  consuming  SBIF  have  extremely  high  levels  of  serum 
isoflavones [14].  One  study  reported  the  isoflavone  content  of  the  major  brands  of  commercially 
available SBIFs as well as the serum concentrations of isoflavones (including genistein, daidzein and 
its metabolite, equol) in four month old infants exclusively fed SBIF, cow’s milk formula, or human 
breast milk. The levels of isoflavones in five different SBIFs varied from 32 to 47 mg isoflavones/L of 
formula [9,14]. Thus, infants fed these formulas are exposed to 5.7–11.9 mg isoflavones/kg body 
weight during the first four months of life. Compared to adults consuming a soy rich diet, which could 
contain approximately 0.71 mg/kg body weight (assuming a body weight of 70 kg) [15], infants fed 
SBIF are exposed to a 6–11 fold higher level of isoflavones on a body weight basis than adults. 
Additionally,  circulating  isoflavone  levels  of  these  infants  were  13,000–22,000  times  greater  than 
circulating levels of 17--estradiol [9]. 
1.2. Studying the Effects of Soy Isoflavones in SBIF 
Currently, there is debate regarding the physiological impact of soy isoflavone consumption and 
whether or not it warrants concern for infants fed SBIF. Because only one study has reported on 
reproductive health outcomes at adulthood [16], it is not possible to know whether feeding infants 
SBIF is associated with negative effects on reproductive health. Thus, due to the paucity of human 
data, it may be useful to assess findings from studies using animal models to more fully understand 
effects in humans. Unquestionably there are considerations that need to be made when extrapolating Nutrients 2010, 2  
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findings  from  animal  models  to  humans  (Table  1).  Human  and  animal  studies  have  different 
challenges  and  we  propose  that  both  types  of  studies  are  important  to  achieve  a  comprehensive 
understanding of the biological effects of soy isoflavones on reproductive health.  
Table 1. The challenges of designing and conducting studies in humans or using rodent 
models to study the effects of soy isoflavones on reproductive health. 
Humans Studies  Rodent Models 
  Long-term time commitment to follow birth 
cohort through to adulthood;  
  Extensive and long-term continuous funding 
required;  
  Consideration of environmental factors that 
can impact reproductive health (i.e., exposure 
to endocrine disruptors, physical activity, 
smoking, age, education, diet and disease 
history);  
  Limited to measurement of noninvasive 
outcomes (i.e., organ size, menstrual cycle, 
fertility) that may provide limited insight into 
mechanisms of action. 
  Species-related differences in digestion, 
absorption and metabolism of isoflavones;  
  Administering purified isoflavone or 
isoflavones as part of SBIF;  
  Route of isoflavone administration: Oral 
feeding versus subcutaneous injection;  
  Frequency of isoflavone administration: 
Once daily dose or multiple doses per day;  
  Composition of soy isoflavone mixture to 
mimic the ratio and combination of 
isoflavones present in SBIF;  
  Equating the timing of the life cycle between 
rodents and humans. 
1.2.1. Challenges of Human Studies 
Some of the major challenges of designing studies and collecting human data regarding the effects 
of soy isoflavones on reproductive health are outlined in Table 1. 
1.2.1.1. Long-Term Time Commitment  
Determining  the  effect  of  SBIF  on  human  reproductive  development  requires  a  long-term 
commitment, both on the part of the investigator(s) as well as the subjects. Ideally, children would be 
monitored before puberty and until sexual maturity is reached. This would allow potential differences 
in  reproductive  organ  development  to  be  discerned.  Furthermore,  reproductive  capacity  should  be 
assessed throughout potential child-bearing years. As with all long-term studies, subject compliance 
and retention over this long time period will be difficult. Retrospective cohort studies of individuals 
who  consumed  SBIF  are  another  strategy  and  indeed  one  such  study  has  been  reported  [16].  A 
limitation of retrospective studies is recall bias. Unless a birth cohort with detailed records of infant 
feeding from birth through at least the first months of life exist, it is difficult to accurately determine to 
the type of feeds an infant received. It is also useful to collect data at various life stages in order to 
determine if both reproductive development and capacity are normal. Retrospective cohort studies are 
still  very  time  intensive  and  recruiting  sufficient  number  of  participants  and  controlling  for  the 
multitude of factors that may affect reproductive capacity may be particularly challenging. Nutrients 2010, 2  
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1.2.1.2. Expensive and Long-Term Funding Required 
From a practical standpoint, prospective studies in particular, as discussed above, are costly and 
require long-term funding. Retrospective studies would also require a substantial level of funding.  
1.2.1.3. Environmental Factors 
Accounting and controlling for various environmental differences that subjects either would be, or 
were exposed to, is difficult to control. Other factors such as level of physical activity, dietary patterns, 
smoking and history of disease may be possible to correct for but it is considerably more difficult to 
determine the level of subject exposure to known environmental endocrine disruptors. Examples of 
such estrogenic compounds include chemicals used in cosmetics and persistent organic pollutants [17].  
1.2.1.4. Limited to Measurement of Noninvasive Outcomes 
Undisputed is the fact that data from human subjects is ideal to determine if isoflavones in SBIF 
modulates reproductive development. However, human studies are limited to measurement of fairly 
noninvasive  outcomes  such  as  pubertal  maturation,  sexual  orientation,  body  weight,  menstrual 
characteristics,  congenital  characteristics  of  subject  offspring  and  hormone  dependent  cancers 
(i.e., testicular, ovarian, breast, prostate). Indeed, the one retrospective study to date included many of 
these  measurements  [16].  Measurement  of  serum  hormone  levels,  reproductive  organ  size  and 
morphology  would  provide  a  more  comprehensive  understanding  of  biological effects  of  SBIF  in 
human infants.  
1.2.2. Challenges of Using Rodent Models 
Some of the major challenges of designing studies and collecting rodent data to determine the 
effects of soy isoflavones on reproductive health are outlined in Table 1. 
1.2.2.1. Species Related Differences 
Rats, mice, marmosets and piglets have been used in animal studies and it is known that there are 
some species related differences in absorption and metabolism of soy isoflavones [18]. There are, 
however, some aspects important similarities in isoflavone metabolism among species. For example 
mouse pups, like human infants, do not produce equol which is the more estrogenic metabolite of 
daidzein [14].  
1.2.2.2. SBIF versus Purified Soy Isoflavones 
Isolated soy isoflavones are frequently used in animal studies but it is unknown whether they act 
differently when present in SBIF, a complex mixture of phytochemicals and peptides. Using rodent 
models  it  is  not  possible  to  deliver  sufficient  levels  of  isoflavones  by  using  SBIF  as  the  volume 
required is too high. This is likely the basis for why most investigators have administered purified 
isoflavones rather than SBIF for rodents. A few studies have fed soy formula directly to animals, such Nutrients 2010, 2  
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as marmosets or pigs and thus when reviewing the animal data it is important to know the form of 
isoflavones provided.  
1.2.2.3. Route of Administration—Oral versus Subcutaneous Injection 
Additional considerations include the route of isoflavone administration in a study. There have been 
differences reported in the serum isoflavone levels in rodents depending on whether the isoflavone 
mixture was given orally or delivered by subcutaneous injection [19]. We have previously shown that 
subcutaneous injection of genistein and daidzein in mice results in serum isoflavone levels that are 
comparable to human infants fed SBIF [20]. This is significant because it suggests that the use of 
subcutaneous injection is useful even though injected genistein bypasses first pass metabolism in the 
gut. Oral feeding in rodent neonates is possible but due to the small size of the pup it is difficult to 
ensure that all of the isoflavone mixture is consumed during an oral feeding (measurement of serum 
levels are needed to determine the level of isoflavone exposure). Another issue with oral feeding from 
birth through the first days of life includes the risk of aspiration requiring premature euthanization. 
One study used a combination of subcutaneous injection and oral feeding and examined the effects of 
genistein on postnatal development from birth until PND 21 in rat pups. The authors state that it was 
not technically practical to orally gavage the rat pups from birth and thus subcutaneous injections were 
used from birth until PND 7 [21] and pups were fed orally thereafter. Oral feeding may be more 
desirable to more closely mimic the human infant scenario, and whether differences in metabolism 
result in different biological effects requires further study. 
In one study, mice were given varying doses of genistein in order to determine the oral dose that 
would achieve serum levels close to human infants consuming SBIF. It was determined that 5–20 mg 
oral genistein/kg body weight did not have a measurable effect on serum genistein levels but an oral 
dose of 50 mg genistein/kg body weight resulted in serum levels of 2–3 µM  [22] and others have 
shown that subcutaneous injection at this same dose (50 mg/kg body weight) also results in similar 
serum levels (1–5 μM) [23]. This is similar to the 1–5 µM  total serum isoflavone levels observed in 
human infants [14]. This demonstrates that there may be no difference in serum levels after oral or 
subcutaneous administration and that the dose of 50 mg isoflavones/kg body weight may achieve 
serum  isoflavone  levels  close  to  human  infants  [22,23].  However,  whether  different  routes  of 
administration (i.e., oral or subcutaneous injection) result in similar or dissimilar serum isoflavone 
levels requires direct comparison within a study. Another study that administered markedly lower 
doses  of  isoflavones  (5  mg  genistein/kg  body  weight  and  2  mg  daidzein/kg  body  weight  by 
subcutaneous injection) resulted in serum levels of 2.61 ±  0.97 μM and 1.07 ±  0.19 μM respectively [20]. 
Such  findings  demonstrate  the  need  for  further  study  in  order  to  determine  appropriate  oral  and 
subcutaneous doses to mimic physiological relevant serum isoflavone levels.  
1.2.2.4. Frequency of Exposure 
Notably, studies that have successfully used oral feeding have administered the mixture once per 
day. In order to truly represent the human infant experience, multiple oral feedings would be required. 
This aspect requires future study. Nutrients 2010, 2  
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1.2.2.5. Composition of Isoflavones 
Genistein, which is considered the most abundant soy isoflavone found in SBIF [14] has been the 
focus of investigation and is often administered in isolation. Genistein, however, is not the only active 
isoflavone in SBIF. Daidzein is also present in soy formula and accounts for approximately 28.7% of 
total  isoflavone  content  (genistein  accounts  for  approximately  67.1%  of  total  isoflavones)  [14]. 
Therefore, the ratio and dose of isoflavones should be comparable to SBIF, and both genistein and 
daidzein should be administered if isolated soy isoflavones are used rather than SBIF. 
1.2.2.6. Equating the Timing of the Life Cycle of Rodents with that of Humans 
The timing of when isoflavone exposure should take place using an animal model, in order to 
mimic the first year of life in humans, is debatable. Mice suckle for the first 21 days of life and thus it 
makes sense that soy isoflavone exposure should take place during the age of suckling to mimic the 
stage of development in which human infants may be fed SBIF. A difficulty is that mice also start to 
reach sexual maturation shortly thereafter, being able to breed by six weeks of age, whereas humans 
have a much longer duration before sexual maturation takes place.  
1.3. Safety of Soy Isoflavones for Reproductive Health  
Several countries have controlled the availability of SBIF because of concern regarding safety of 
isoflavone exposure in early life and reproductive development. In Europe, for instance, SBIF is only 
available by prescription [24]. In 1996, the United Kingdom Committee on Toxicity of Chemicals in 
Foods, Consumer Products and the Environment considered the presence of phytoestrogens, such as 
soy isoflavones, in SBIF and subsequently supported the advice of the U.K. Department of Health, that 
human breast milk and cow’s milk are preferred sources of nutrition for infants and SBIF should only 
be recommended when there is clinical indications [25]. The Working Group identified the need for 
further studies, and stated that due to a paucity of data it is not possible to make a final conclusion. The 
Canadian  Paediatric Society,  Dietitians of  Canada, Health  Canada and  the American  Academy  of 
Pediatrics as well as many other organizations recognize that breastfeeding is the optimal method for 
feeding infants [9,10]. The use of SBIFs is recommended for only those infants who cannot have 
dairy-based products because of health, cultural or religious reasons. Nonetheless, significant numbers 
of infants are fed SBIFs during the first year of life. 
In  the  United  States,  The  National  Toxicology  Program  Center  for  the  Evaluation  of  Risks  to 
Human Health Reproduction (NTP-CERHR) convened in December of 2009 to evaluate the safety of 
SBIF. A panel of experts reviewed and evaluated the quality and strength of available scientific data 
regarding early exposure to SBIF or its isoflavones and how it may impact human development [26]. 
In 2006, the NTP previously convened to evaluate soy formula and genistein, but did not complete the 
evaluation or issue a final statement due to insufficient data [27]. The substantial number of studies 
that were released from 2006–2009 prompted the NTP-CERHR to revisit this topic. The NTP-CERHR 
and expert panel has since concluded that there is ―minimal‖ concern due to a paucity of data focusing 
on early, critical stages of the life cycle [26]. Moreover, it was stated that the design of some studies 
are not ideal for evaluating the safety of SBIF. These aspects have been summarized and discussed in Nutrients 2010, 2  
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secton 1.2 and Table 1. However, the relatively high number of studies in experimental animals, and a 
few studies in humans, reported some effect of isoflavones on reproductive health, and this raised the 
level of concern from ―negligible‖ to ―minimal‖. The report also stated that there is insufficient human 
data to form a definitive conclusion [26]. 
The objective of this review is to examine the current scientific data regarding soy isoflavones and 
effects on reproductive health. Since there are few studies examining the effects of SBIF in humans, it 
is necessary to include animal studies, mainly in rodents, to discern the effect of soy isoflavones on 
human health but keeping in mind the limitations/challenges in extrapolating findings from animal 
studies to human infants. Before discussing the findings from these studies it is useful to review the 
indicators  of  reproductive  health  that  have  been  measured  and  what  information  they  provide 
regarding effects on reproductive health (Table 2). These indicators are grouped according to whether 
they are indicators of sexual maturation or endocrine disruption. Multiple measures should be used 
when determining the effect of an estrogenic compound on reproductive development.  
Table 2. Indicators of sexual maturation and endocrine disruption in rodent models. 
Sexual Maturation 
Preputial Separation 
The separation of the foreskin of the penis from the glans, preputial 
separation (PPS) is an early marker of the progression of puberty. 
Vaginal Opening 
The initial marker of the rise in circulating estrogen that signifies 
the onset of puberty and first ovulation followed by the start of 
estrous cycling. 
Endocrine Disruption 
Anogenital Distance (AGD) 
The distance between the anus and genital protuberance in 
newborns of various species including mouse and rat is used as the 
sole external sex-differentiating marker (longer in males compared 
to females) and is used to determine whether or not endocrine 
disruption has occurred. Under-masculinization is said to have 
occurred if AGD is shortened compared to control animals. 
Sex Organ Histology 
Changes in morphology of the mammary gland, ovary, uterus, 
testes are indicators of estrogenic effects that may ultimately be 
manifested as enhanced or reduced fertility. 
Sex Organ Weight 
Higher weight of uterus, ovaries, testes, or prostate may indicate 
estrogenic effects due to higher rates of cell proliferation within 
the organ. 
Serum Hormones 
Measurement of sex steroid hormones (i.e., LH, FSH, GnRH, 
estradiol, progesterone, testosterone) demonstrates estrogenic 
perturbations in the endocrine system. 
Estrogen Receptor Activity 
Elevated transcription of ER-ß  or ER-α is indicative of higher 
estrogenic activity. 
Estrous Cycle 
Length of time spent in each phase of estrous cycle can be used to 
understand if fertility may be altered, i.e., if an animal is in 
prolonged diestrus, lower fertility may result. 
Lordosis Quotient 
A measure of sexual behavior and is calculated by dividing the 
number of lordoses (inward curving of a portion of the vertebral 
column) by the number of mounts. Nutrients 2010, 2  
 
 
1163 
2. Results and Discussion  
Review of studies to date show that interventions with isoflavones have been conducted at different 
life-stages, and in some studies the intervention occurred over more than one life-stage. This review 
focuses on studies in which animals were directly exposed to soy isoflavones during suckling since the 
objective was to review studies that relate to infants fed SBIF. The doses of soy isoflavones and the 
route of administration used in the studies reviewed are summarized in Table 3. Of note is that few 
studies measured serum levels of soy isoflavones. Without knowing serum levels of isoflavones, it is 
difficult to directly compare findings to human infants. 
Table 3. Summary of isoflavone doses, route of administration and serum measurements in 
rodent models studying reproductive health. 
  Dose 
Route of 
delivery 
Serum Isoflavone Levels  Ref. 
Females 
0.0001–100 mg genistein or 
daidzein/kg body weight 
SC  NM *  [28] 
0.5, 5, 50 mg genstein/kg body 
weight 
SC  NM *  [29-31] 
12.5, 25, 50 or 100 mg 
genistein/kg body weight 
Oral  NM *  [32] 
50 mg genistein/kg body 
weight 
SC 
Oral 
NM *  [33-35] 
5, 20, 50, 100 mg genistein/kg 
body weight 
Oral 
5, 20 and 100 mg genistein/kg 
body weight: below desired range;  
50 mg genistein/kg body weight 
resulted in desired serum range of: 
2–3 µM   
[22] 
Oral genistin: 6.25, 12.5, 25 or 
37.5 mg/kg body weight/day;  
Oral genistein: 25, 37.5, 
75 mg/kg/day 
Oral 
Serum levels of oral GIN and 
GEN were measured at 37.5 
mg/kg body weight;  
GEN AUC/dose = 2.4;  
GIN AUC/dose = 0.34 
[19] 
Subcutaneous genistein: 12.5, 
20, 25 mg/kg body weight 
SC  NM *  [19] 
0.2, 2, 4, 40 mg genistein/kg 
body weight (sexes combined) 
SC 
SC 
4 mg genistein/kg body weight:  
0.99 µ g/equivalents/h/mL;  
40 mg/kg body weight:  
5.82 µ g/equivalents/h/mL 
[21] 
Oral 
40 mg genistein/kg body weight:  
0.53 µ g/equivalents/h/mL 
[21] 
83 mg genistein or daidzein/kg 
body weight 
SC  NM  [36] 
500 mg genistein/kg body 
weight 
SC  NM  [37] Nutrients 2010, 2  
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Table 3. Cont. 
Males 
4 mg genistein/kg body weight  SC  NM  [38] 
1.6–3.5 mg isoflavones/kg 
body weight 
Oral  NM  [39,40] 
0.2, 2, 4, 40 mg genistein/kg 
body weight (sexes combined) 
SC 
4 mg genistein/kg body weight:  
0.634 µ g/equivalents/h/mL;  
40 mg/kg body weight:  
5.82 µ g/equivalents/h/mL 
[21] 
Oral 
40 mg genistein/kg body weight:  
0.53 µ g/equivalents/h/mL 
[21] 
12.5 25, 50 or 100 mg 
genistein/kg body weight 
Oral  NM  [32] 
* Previously measured serum genistein levels of 1–5 μM after subcutaneous injection of 50 mg 
genistein/kg  body  weight  are  reported  [23];  Human  infants  are  exposed  to  5.7–11.9  mg  soy 
isoflavones/kg body weight resulting in serum concentrations of 1–5 µ M total isoflavones [14]. 
2.1. Male and Female Reproductive Health: Human Studies (Table 4) 
To date, few studies have investigated the impact of early life consumption of SBIF on reproductive 
function in adult life (Table 4). Strom et al. reported no differences in more than 30 reproductive 
health outcomes including the age of onset of puberty and reproductive function in males. Prolonged 
menstruation as well as increased discomfort during menstruation was more frequently reported in the 
female group [16]. Increased vaginal cell maturation has been reported in female infants at six months 
of age, and was considered to be an estrogenic effect attributed to the consumption of SBIF in early 
life [41]. Other outcomes, including vaginal discharge and breast and genital development were not 
altered [41]. Another study, which focused on infants at two years of life did however demonstrate 
differences in breast development [42]. For example, breast tissue was more prevalent in infants fed 
SBIF  at  two  years  of  life  compared  to  those  fed  cow’s  milk-based  formula  or  breast  milk  [42]. 
Currently, The Beginnings Study, a longitudinal prospective study, is in progress at the Arkansas 
Children’s Nutrition Center to compare growth, development, and health of breastfed or formula-fed 
children [43]. Findings to date have shown that formula-feeding itself, without discriminating between 
type of formula, results in greater ovarian volume, increased numbers of ovarian cysts per ovary and 
lower testicular volume [43]. Consideration in the interpretation of these findings is that 32% of infants 
in the SBIF group did not consume SBIF until 4–8 weeks of age. Because timing of exposure may 
modulate effects of later health it will be important to further investigate how timing of exposure may 
influence reproductive outcomes at later stages of development (i.e., beyond four months of age). 
2.2. Female Reproductive Health: Animal Studies (Table 5) 
Studies that investigated the long-term consequences of soy isoflavone exposure during suckling 
have demonstrated differing effects at adulthood (Table 5). 
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Table 4. Studies examining the effect of soy isoflavone exposure in early life on human development. 
Objective  Sample Size  Age of Subjects 
Intervention 
Duration 
Reproductive Health Outcomes  Findings 
Retrospective cohort study 
to determine the association 
between soy infant formula 
consumption and health in 
adulthood with focus on 
reproductive health;  
 
Self-reported pubertal 
maturation, menstrual and 
reproductive history, height 
and usual weight [16]. 
n = 248 
SBIF 
 
n = 563 
cow’s milk 
formula 
Adults aged 20–34  Adults as infants 
were treated from 
age 9 days or before 
to16 weeks of age;  
 
Cow’s milk formula;  
 
SBIF (soy isoflavone 
content of the 
formula was 
unknown) 
Women: adult
 height, weight 
body mass
 index, pubertal 
maturation number of days 
between
 periods number of days 
requiring pads or tampons, 
regularity
 of menstrual period, 
menstrual flow, pain with 
menstrual period, physical 
symptoms of pain, breast 
tenderness during menstrual 
cycle, premenstrual
 symptoms, 
breast size, reproductive 
outcomes, and education level 
attained as a proxy measure for 
intelligence;  
Men: adult height, usual weight, 
and education
 level, pubertal 
maturation and pregnancy 
outcomes in sexual partners 
impregnated
 by the male study 
subjects, congenital
 
malformations in the offspring of 
study subjects, hormonal 
disorders,
 testicular cancer in 
men, and homosexual orientation. 
Men and Women:  
No statistically 
significant differences 
were reported between 
groups in either men or 
women for more than 
30 outcomes;  
Women:  
Significantly longer 
menstrual bleeding and 
greater discomfort 
during menstruation. Nutrients 2010, 2  
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Table 4. Cont. 
To pilot techniques for 
assessing infants’ responses 
to the withdrawal from 
maternal estrogen and 
gathered data on breast and 
genital development in 
infants at different ages in 
infants who have consumed 
SBIF, cow’s milk formula or 
exclusively breast milk [41] 
n = 72 equally 
distributed in 
SBIF, cow’s 
milk formula 
and exclusive 
breast fed 
37–41 weeks 
of age 
37–41 weeks 
of age until 
6 months of 
age 
Breast adipose tissue;  
 
Breast bud and testicular 
volume;  
 
Observed breast and 
genital development;  
 
Vaginal wall cytology;  
 
Vaginal discharge 
Breast tissue was maximal at birth 
and disappeared in older children, 
consistent with waning maternal 
estrogen;  
 
Genital development did not 
change by age;  
 
Vaginal wall cells showed 
maximal estrogen effect at birth 
and then reverted as normal;  
 
Female infants on SBIF appeared 
to show reestrogenization at 6 
months, by increased maturation 
in vaginal cells 
To evaluate the estrogenic 
effect of soy-based formulas 
in female infants [42] 
n = 50–92 SBIF 
for more than 
3 months 
 
n = 602–232 
Milk group (both 
breast milk and 
cow’s milk) 
3–24 months 
of age 
3–24 months 
of age 
Breast development  No differences in breast bud 
prevalence during the first year of 
life;  
 
Infants fed SBIF did not 
demonstrate a decline in the 
prevalence of breast tissue during 
the second year of life, unlike 
other groups Nutrients 2010, 2  
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Table 4. Cont. 
To determine if differences 
exist in hormone-sensitive 
organ size between infants 
who were fed soy formula 
(SBIF), milk formula (MF), 
or breast milk (BM) [43] 
n = 40 BM 
 
n = 41 MF 
 
n = 39 SBIF 
Age 4 months;  
 
SBIF exclusively 
fed from birth up to 
8 weeks of age and 
continuing until 
4 months of age 
(32% did not 
switch to SF until 
4–8 weeks of age);  
 
MF from birth to 
4 weeks until 
4 months of age;  
 
BM from birth until 
4 months of age 
BM, MF or SBIF 
for 4 months 
Anthropometry;  
 
Body composition;  
 
Breast buds, uterus, 
ovary, prostate and 
testicular volume 
In both formula groups males had 
lower testicular volume, and females 
had greater ovarian volume, increased 
numbers of ovarian cysts per ovary;  
 
Other measures were not significantly 
different between the control and 
SBIF groups Nutrients 2010, 2  
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Table 5. Studies in female animal models examining the effects of soy isoflavone exposure during early life. 
Objective 
Sample 
Size 
Subjects 
(age at time of 
intervention) 
Intervention: Route 
of administration 
and dosage 
Duration of 
Intervention 
Reproductive 
Health Outcomes 
Findings 
To determine if the 
orally administered 
genistin (GIN), the 
glycosylated form 
of genistein 
(GEN), causes 
adverse effects on 
the developing 
reproductive tract 
 
GIN is most 
predominant in soy 
isoflavone 
formulas, but 
infants consuming 
SBIF have high 
circulating levels 
of GEN [19] 
n = 4–16 
mice/group 
CD-1 mice, 
PND 1 
SC: genistein: 12.5, 
20, 25 mg/kg body 
weight  
 
Oral genistin (GIN): 
6.25, 12.5, 25 or 
37.5 mg/kg body 
weight 
 
Oral genistein 
(GEN): 25, 37.5, 
75 mg/kg/day 
PND 1–5  SC GEN, Oral 
GEN, Oral GIN 
Uterine wet weight 
gain 
 
Induction of 
estrogen-responsive 
gene, lactoferrin (LF) 
 
GIN Group only  
Vaginal opening 
 
Estrous cycling 
 
Fertility 
 
Morphologic 
alterations in 
ovary/reproductive 
tract 
SC GEN, Oral GEN, Oral GIN 
20–33% more oral GIN was 
needed to elicit uterine wet 
weight gain compared to SC 
GEN but similar response was 
observed 
 
Oral GEN uterine wet weight 
gain only observed at much 
higher doses of 75 mg 
genistein/kg body weight  
 
Induction of LF gene  
 
Oral GIN:  
Increased incidence of 
multioocyte follicles in the 
ovaries 
 
Delayed vaginal opening 
Altered estrous cycling 
 
Decreased fertility  
 
Delayed parturition Nutrients 2010, 2  
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Table 5. Cont. 
To develop a mouse 
model that more closely 
mimics the oral genistein 
exposure and total serum 
genistein concentrations. 
To assess reproductive 
and nonreproductive 
organs after dosing and 
during development [22] 
Not 
determined 
C57BL/6 
mice, 
PND 1 
Oral genistein-soy 
formula emulsion: 5, 
20, 50, 100 mg/kg 
body weight 
PND 1–5  Serum genistein 
concentration 
 
Thymic and 
uterine weights 
 
Follicle numbers 
 
Immunohistoche
mistry for 
progesterone 
receptor 
5, 20, 100 mg genistein/kg body 
weight: below desired range of 
serum genistein 
50 mg genistein/kg body weight 
Increased uterine weight 
Downregulation of progesterone 
receptor in uterine epithelia 
Increased incidence of multioocyte 
follicles 
Decrease in thymic weight 
Altered estrous cycling 
Normal fertility 
To determine the effects 
of oral exposure to 
genistein in order to 
assess human risk 
following oral ingestion 
of genistein [21] 
Not 
determined 
Alderley 
Park rat 
PND 1 
PND 1–6 
SC 
Genistein: 
0.2 or 2 mg/kg body 
weight 
PND 7–21 
Oral gavage 
Genistein:  
4 or 40 mg/kg body 
weight 
Control: corn oil 
PND 1–21  Serum LH, FSH, 
estradiol, 
progesterone 
 
Vaginal opening 
 
Estrous cycling 
 
Sex organ 
weights 
 
GnRH 
40 mg genistein/kg body weight: 
Increased uterus weights at PND 
22 
 
Advanced mean day of vaginal 
opening 
 
Induced permanent estrus 
 
Decreased progesterone in mature 
females 
 
4 mg genistein/kg body weight: 
No effects Nutrients 2010, 2  
 
 
1170 
Table 5. Cont. 
To measure the estrogenic 
responses of several 
phytoestrogens including 
genistein, daidzein and 
compare them over a dose 
range and measuring the 
transcriptional activation 
of the estrogen receptor 
(ER) and an in vivo 
immature mouse 
uterotrophic assay [28] 
Not 
determined 
CD-1 
mice, 
PND 17 
SC 
Genistein and daidzein 
doses 0.00001 to 
1000 mg/kg body weight 
Positive controls:  
Diethylstilbestrol (DES) 
17β-estradiol: 0.01 to 
1,000,000 µ g/kg body 
weight 
Negative control: corn oil  
3 consecutive 
days (PND 17, 
18,19) 
Uterine wet 
weight 
 
Uterine 
epithelial height 
 
Uterine gland 
number 
Daidzein treatment:  
Did not demonstrate any increase 
in uterine epithelial cell height;  
Increase in uterine gland number;  
Did not demonstrate an increase in 
uterine wet weight;  
Genistein treatment:  
Increase in uterine wet weight;  
Increase in uterine epithelial cell 
height;  
Increase in uterine gland number 
To determine the 
biochemical effect of 
genistein as the induction 
of ectopic expression of 
ER in granulosa cells, a 
morphological effect as 
the induction of 
multioocyte follicles 
(MOFs) in the ovary, and 
a functional effect as the 
altered ovarian response 
to superovulation 
treatment [29] 
n = 16/group  CD-1 
mice, 
PND 1 
SC 
 
Genistein: 1, 10, 
100 µg /pup/day 
(approximately 0.5, 5 or 
50 mg/kg body weight)  
5 days 
PND 1–5 
ER-ß  and ER-α 
expression and 
distribution in 
ovarian tissues 
 
The impact of 
genistein on ER 
expression, 
ovulation and 
the development 
of multioocyte 
follicles 
ER-β transcript expression 
predominated in the ovaries in all 
stages of life and over ER-α and 
increased with age 
Genistein did not change ER-β 
expression but ER-α expression 
increased on days 5 and 12 
ER-β was immunolocalized to 
granulosa cells 
ER-α was immunolocalized in 
interstitial and thecal cells 
Genistein caused major increase in 
ER-α expression in granulosa cells 
Superovulated mice had an 
increase in the number of ovulated 
oocytes at the lowest dose 
Dose-related increase in 
multioocyte follicles (MOFs) Nutrients 2010, 2  
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Table 5. Cont. 
To determine the 
the processes 
involved in 
altered mammary 
gland growth and 
development 
after neonatal 
genistein 
treatment [30] 
n = 3–8/group  CD-1 
mice, 
PND 1 
SC 
 
Genistein 0.5, 
5 or 50 mg/kg 
body weight  
PND 1–5  Development of 
the mammary 
gland 
4-week: No morphological differences were 
observed in development 
 
5-week: Gen50 group had stunted development(less 
branching ) decreased numbers of terminal end buds 
 
6-week: Gen50 had decreased number of terminal 
end buds, Gen 0.5 treated mice had advanced 
development with increased ductal elongation 
Increased levels of progesterone receptor protein 
and estrogen receptor-β mRNA in Gen0.5-treated 
mice compared with controls 
ER-α expression decreased after all doses of 
Gen treatment 
Gen50 treated mice were unable to deliver live pups 
To study the 
effects of 
neonatal 
genistein 
exposure on 
attainment of 
puberty and 
fertility [31] 
Not 
determined 
CD-1 
mice 2, 4, 
6 months 
of age 
SC 
 
Genistein: 
0.5, 5 or 
50 mg/kg body 
weight 
PND 1–5  Vaginal opening 
Fertility 
Implantation and 
pregnancy 
Ovarian function 
(number of corpus 
luteum and ovarian 
capacity) 
Estrous cyclicity 
Serum hormone 
levels (estradiol 
and progesterone) 
before puberty 
Genistein treated mice had prolonged estrous cycles 
that had a dose and age-related increase 
Pregnancy loss was attributed to fewer implantation 
sites and increased resorption 
Low dose genistein treated mice had increased 
numbers of corpora lutea compared to controls 
High dose genistein treated mice had fewer corpora 
lutea 
Similar levels of serum estrogen, progesterone and 
testosterone were observed before and during 
pregnancy 
Mice treated with Gen-50 did not deliver live pups Nutrients 2010, 2  
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Table 5. Cont. 
To evaluate 
whether early 
exposure of 
neonates to 
genistein has any 
effect on the 
development of 
sexual organs 
and/or 
reproductive 
performance [32] 
n = 10–24/group  Sprague-
Dawley 
rats PND 1 
Oral gavage 
 
Genistein: 
12.5, 25, 50 or 
100 mg/kg body 
weight 
 
Control: corn oil 
PND 1–5  Fertility 
 
Vaginal Opening 
 
Estrous cycling 
 
Histopathological 
changes in the 
reproductive 
organs 
Fertility was disrupted at 100 mg 
genistein/kg body weight 
 
Age at vaginal opening was not 
altered 
 
Estrous cycle: genistein-treated had 
cycle had variation in the amount of 
time spent in each phase and this was 
not dose responsive, cycle length was 
normal 
 
Histopathological changes in the 
uterus and ovary at 100 mg 
genistein/kg body weight 
To study the 
formation of 
multioocyte 
follicles (MOFs) 
and potential 
disruption of the 
development of the 
ovary by genistein 
on ovarian 
differentiation [33] 
n = 24–48/group  CD-1 mice, 
PND 1 
SC 
 
Genistein 50 mg/kg 
body weight 
(~100 μg/pup/day) 
PND 1–5  Ovarian 
differentiation 
Genistein treatment: 
 
Fewer single oocytes 
 
Higher percentage of oocytes not 
enclosed in single follicles 
 
Oocytes nest breakdown was 
prolonged 
 
Fewer oocytes undergoing apoptosis 
on neonatal day 3 Nutrients 2010, 2  
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Table 5. Cont. 
To determine the long-term 
carcinogenic potential in 
mice treated neonatally 
with genistein or DES with 
equal estrogenic dose [34] 
n = minimum 
8/group 
CD-1 mice, 
PND 1 
SC 
 
Genistein: 
50 mg/kg body 
weight 
 
DES: 
0.001 mg/kg 
body weight 
 
Negative control:  
corn oil 
5 days 
PND 1–5 
Incidence of 
uterine 
adenocarcinoma 
 
Uterine weight 
Corpora lutea 
absence 
 
Abnormalities 
in the oviduct 
Ovarian tumor 
Higher incidence of uterine 
adenocarcinoma at 18 months 
with genistein and DES;  
 
Higher uterine weight gain with 
genistein and DES;  
 
Higher absence of corpora lutea 
with genistein and DES 
To elucidate the mechanism 
by which gensitein leads to 
infertility [35] 
Not determined  CD-1 mice, 
PND 1 
SC 
 
Genistein 
50 mg/kg body 
weight 
 
Control: corn oil 
PND 1–5  Oocyte 
developmental 
competence 
 
Timing of 
embryo loss 
Genistein treatment: 
Females were not capable of 
supporting normal implantation of 
control embryos 
 
Oocytes were competent but the 
oviductal environment and the 
uterus have abnormalities that 
result in reproductive failure 
 
Complete infertility observed Nutrients 2010, 2  
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Table 5. Cont. 
To examine the 
effect of 
phytoestrogens 
on female 
sexual behavior 
and ovarian 
cyclicity [36] 
n = 9–10/group  Wistar rats 
PND 1 
SC 
 
Genistein 
1 mg/day 
 
Daidzein 
1 mg/day 
 
Control: sesame oil 
PND 1–5  Estrous cycle 
 
Vaginal Opening 
 
Ovary histology 
 
Lordosis quotient 
(feminine sexual 
reflexes) 
Genistein treatment:  
Prolonged estrous cycle 
Smaller ovaries and no corpora 
lutea compared to control or DZ 
group 
Low lordosis quoteint 
Daidzein treatment:  
Corpora lutea seen but ovaries 
were smaller compared to 
controls 
High lordosis quotient 
To investigate 
the potential of 
genistein to 
protect against 
the 
development of 
breast cancer 
and to cause 
reproductive 
and 
developmental 
toxicity [37] 
Not determined  Prepubertal 
female, 
suckling, 
Sprague-
Dawley rats 
SC 
 
Genistein 500 mg/kg body 
weight 
 
Oral gavage Carcinogen: 
Dimethylbenz[a]anthracene 
(DMBA) 80 mg/kg body 
weight 
Genistein: 
3 days, 
every 
second day 
PND 16, 
18, 20  
 
DMBA: 
PND 50 
Mammary gland 
differentiation and 
cell proliferation in 
the presence of 
carcinogen DMBA;  
Offspring body 
weights;  
Anogential 
distance;  
Vaginal opening;  
Estrus cycle length;  
Follicular 
development 
Genistein treatment:  
50% reduction in chemically 
induced mammary tumorgenesis 
 
Increased mammary gland 
differentiation in immature rats 
leading to mammary gland less 
susceptible to mammary cancer 
 
No significant changes in 
fertility, number of male and 
female offspring, body weight, 
anogenital distance, vaginal 
opening, testes descent, estrus 
cycle, or follicular development 
among groups 
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2.2.1. Reproductive Organ Morphology 
Studies have shown that early exposure to soy isoflavone enhances differentiation of the mammary 
gland,  leading  to  a  mammary  gland  that  is  less  susceptible  to  chemically-induced  mammary 
cancer [37]. Furthermore, this effect is present at high levels of exposure, (subcutaneous injection of 
500  mg  genistein/kg  body  weight)  and  did  not  alter  fertility  and  age  at  puberty  onset.  Genistein 
treatment resulted in fewer terminal end buds and advanced development and ductal elongation. It is 
known that terminal end buds are the most susceptible to carcinogens as they are the least mature 
terminal ductal structures [44]. A reduction in the numbers of terminal end buds can therefore explain 
the lower incidence of mammary cancer. Part of the terminal end bud differentiates according to each 
estrous cycle, giving rise to alveolar buds that consist of lobule structures that are more mature and less 
susceptible  to  chemical  carcinogens  [45].  Genistein  treatment  increased  the  number  of  lobules 
indicating a potential protective effect [45]. Previous findings have confirmed that early life exposure 
to  estrogen  causes  differentiation  in  mammary  tissue,  leading  to  a  mammary  gland  that  is  less 
susceptible  to  cancer  [46].  The  mechanism  by  which  genistein  influences  mammary  gland 
development is yet to be elucidated but these findings suggest genistein is exerting an estrogenic effect. 
Another reproductive organ that is sensitive to isoflavone exposure is the uterus. Neonatal mice 
(PND 1–5) treated with genistein had greater uterine gland number (subcutaneous injection of 50 mg 
genistein/kg  body  weight)  and  increased  uterine  weight  and  epithelial  cell  height  at  higher  doses 
(subcutaneous injection of 100 mg genistein/kg body weight) [28]. These results also suggest that 
genistein is mimicking the effect of estrogen on uterus, supporting the hypothesis that genistein acts 
like estrogen in the reproductive system [47]. Interestingly, daidzein did not cause such alterations in 
the uterus, suggesting that daidzein may not have a measurable estrogenic effect on the mouse uterus. 
In  addition,  a  higher  incidence  of  uterine  adenocarcinoma,  corpora  lutea  absence  and  oviduct 
abnormalities have been reported mice following treatment with genistein at subcutaneous injection of 
50 mg genistein/kg body weight [35]. 
2.2.2. Sexual Maturation and Endocrine Function 
Estrogenic substances are known to alter endocrine function, especially when exposure happens 
during critical periods of development [48]. It was previously hypothesized that early exposure to 
compounds with estrogen-like activity may accelerate the age of puberty onset [49]. Earlier age at time 
of  vaginal  opening  has  been  reported  at  doses  of  40  mg  genistein/kg  body  weight  and  this  was 
administered  from  PND  1–21  combining  both  subcutaneous  injection  and  oral  gavage  [21]. 
Interestingly  however,  at  seemingly  higher  doses  of  genistein  (subcutaneous  injection  of  100  mg 
genistein/kg body weight) no change in timing of puberty was observed [32]. Mice were only exposed 
from PND 1–5 however, compared to mice were exposed from PND 1–21, indicating that treatment 
duration may cause differing effects. Lower progesterone and differences in the amount of time spend 
in each phase of the estrous cycle without changes in estrous cycle length have also been observed 
after  the  21  day  treatment  period  [21].  Lordosis  quotient  may  also  be  affected  by  genistein  and 
daidzein exposure; however they have contrasting effects [35]. One study reported a low lordosis 
quotient in the genistein treated group, whereas a higher lordosis quotient was observed in the daidzein Nutrients 2010, 2  
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treated group [35]. These results suggest that genistein and daidzein may affect sexual differentiation 
of the brain, ultimately leading to differences in sexual behavior. 
2.2.3. Fertility 
Impaired fertility in females has been documented after soy isoflavone exposure in the neonatal 
mouse  model  [31,33,35].  Neonatal  genistein  treatment  resulted  in  pregnancy  loss  and  was 
characterized by fewer implantation sites and increased resorption [31]. In the same study, increased 
numbers  of  corpora  lutea  after  low  dose  genistein  treatment  (subcutaneous  injection  of  0.5  and  
5  mg  genistein/kg  body  weight)  and  reduced  numbers  of  corpora  lutea  after  higher  doses 
(subcutaneous injection of 50 mg genistein/kg body weight) were observed. A prolonged estrous cycle 
without changes in serum estrogen, progesterone and testosterone before and during pregnancy was 
also  reported  at  varying  doses  but  showing  a  higher  incidence  of  extended estrous  at  the  highest 
subcutaneous dose of 50 mg genistein/kg body weight [31]. One study reported no corpora lutea after 
genistein  treatment,  smaller  corpora  lutea after  daidzein  treatment  and  both treatments  resulted  in 
smaller ovaries and these were at higher subcutaneous doses of approximately 83 mg genistein and 
daidzein/kg  body  weight  [36].  Other  abnormalities  observed  at  subcutaneous  doses  of  
50  mg  genistein/kg  body  weight  include  the  presence  of  multioocyte  follicles  (MOFs)  [33]. 
Furthermore, MOFs were accompanied by prolonged nest breakdown and fewer oocytes undergoing 
apoptosis [33]. The implications of these findings are noteworthy since in vitro data suggest oocytes 
derived from MOFs have reduced fertilization capacity compared to single oocytes follicles [50]. More 
recently, however, Jefferson et al. has demonstrated that mice treated with the same subcutaneous dose 
of genistein had competent oocytes but these mice could not support normal implantation of control 
embryos and were unable to deliver live pups [35]. Using the same dose and route of administration, 
ER-α but not ER-β transcription was upregulated in mouse ovaries after exposure to genistein [29]. 
This  is  an important  finding as the  mechanism by  which  estrogen exerts its effect on the female 
reproductive  tract  is  predominantly  mediated  through  ER-α  [51].  Early  exposure  to  genistein 
compromises ovarian development and reproductive function in rodent models at serum levels that 
resemble those of human infants. 
2.3. Male Reproductive Health: Animal Studies (Table 6) 
2.3.1. Reproductive Organ Differentiation and Morphology 
Only  two  studies  demonstrated  a  measurable  effect  of  soy  isoflavones  on  male  reproductive 
development  when  exposure  was  limited  to  the  suckling  period  (Table  6).  In  terms  of  organ 
morphology, seminiferous tubule lumen formation and a high sertoli cell nuclear volume that did not 
match the lumen volume per testis has been documented [38]. This measure is used to determine the 
capacity for pubertal spermatogenesis and thus indicates that spermatogenesis may be abnormal [38]. 
Interestingly, these effects were observed at relatively lower doses of genistein (subcutaneous injection 
of 4 mg genistein/kg body weight). In another report that administered genistein by oral gavage, no 
consistent morphological changes in the testes, epididymides, ventral prostate, and seminal vesicles 
were observed at oral doses of genistein up to 100 mg genistein/kg body weight [32].  Nutrients 2010, 2 
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Table 6. Studies in male animals examining the effects of soy isoflavone exposure during early life. 
Objective  Sample Size 
Subjects  
(age at time of 
intervention) 
Intervention: Route of 
administration and 
dosage 
Duration of 
Intervention 
Reproductive 
Health Outcomes 
Findings 
To determine the 
effects of oral 
exposure to 
genistein on 
neonatal rats to 
assess human risk 
following oral 
ingestion of 
genistein [21] 
Not 
determined 
Alderley Park 
rats, PND 1 
PND 1–6: SC 
 
Genistein: 0.2 or 2 mg 
genistein/kg body 
weight 
 
PND 7–21: Oral gavage 
 
Genistein: 
4 mg/kg body weight 
40 mg/kg body weight 
Control: corn oil 
PND 
1–21 
Serum FSH, LH, 
testosterone 
 
Preputial separation 
 
Testes descent 
No consistent effects 
observed in males at 
either dose 
To evaluate 
whether early 
exposure of 
neonates to 
genistein has any 
effect on the 
development of 
sexual organs 
and/or reproductive 
performance [32] 
Not 
determined 
Sprague-Dawley 
rats PND 1 
Oral gavage 
Genistein: 
12.5, 25, 50 or 
100 mg/kg body weight 
 
Control: corn oil 
PND 1–5  Preputial separation 
 
Fertility 
 
Sperm count 
 
Serum testosterone 
 
Histopathological 
changes of 
reproductive organs 
Preputial separation, was 
not effected 
 
Male fertility was not 
effected 
 
Sperm counts and serum 
testosterone was not 
effected 
 
No histopathological 
changes in the gonads Nutrients 2010, 2  
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Table 6. Cont. 
To investigate 
whether neonatal 
exposure of estrogenic 
compounds altered 
pubertal 
spermatogenesis and 
whether the changes 
observed resulted in 
long-term changes in 
testis size, mating or 
fertility [38] 
Not 
determined 
Wistar rats, 
PND 2 
SC 
 
Genistein 
4 mg/kg body weight 
 
Control: corn oil 
PND 2–18  Mating and 
fertility 
Sertoli cell and 
germ cell nuclear 
volume per testis 
Germ cell 
apoptotic index 
Seminiferous 
tubule lumen 
formation 
Plasma FSH 
Few experienced impaired mating and 
fertility and low sample size was 
considered 
Slowed lumen formation 
Increased germ cell apoptotic rate 
High sertoli cell nuclear 
volume that did not match the lumen 
volume per testis 
Suppressed plasma FSH at PND 18 
To establish if there 
are any biological 
consequences of 
consuming soy 
formula milk and to 
study the effects 
observed during and 
at the end of the 
feeding period which 
encompasses the 
period of the neonatal 
rise in testosterone in 
a non-human primate, 
the marmoset [39] 
n = 15/group 
(included 
13 pairs of 
twins) 
Marmoset 
monkeys 
4–5 days 
old 
Hand fed using 1 mL 
syringe 
(3–4 times on 
weekdays, 1–2 times 
on weekends) 
 
Cow’s milk formula 
 
Soy milk formula 
Formulas were 
prepared as per 
instructions and offered 
to the marmoset until 
feeding stopped 
Approximately  
1.6–3.5 mg soy 
isoflavones/kg body 
weight 
5–6 weeks  Histology: testes, 
epididymis, 
pituitary gland 
 
Sertoli and germ 
cell number per 
testes 
 
Leydig cell 
number 
 
Plasma 
testosterone 
Soy formula fed males had mean 
testosterone levels were consistently 
lower than milk formula fed males  
 
No significant changes in numbers of 
sertoli cells or germ cells 
 
Leydig cell number increased by 74% 
 
Paired comparison in soy milk formula 
and cow’s milk formula co-twins 
showed a 53–70% lower serum 
testosterone levels at day 35–45 Nutrients 2010, 2  
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Table 6. Cont. 
To establish if there 
are any consequences 
of consuming soy 
formula milk and to 
study the effects 
observed on fertility 
and testicular 
structure in a 
non-human primate, 
the marmoset [40] 
n = 7/group 
(14 total) 
Marmoset 
co-twin monkeys 
4–5 days old 
Hand fed using 
1 mL syringe 
(3–4 times on 
weekdays,  
1–2 times on 
weekends) 
Cow’s milk 
formula 
Soy milk formula 
 
Formulas were 
prepared as per 
instructions and 
offered to the 
marmoset until 
feeding stopped 
Approximately 
1.6–3.5 mg soy 
isoflavones/kg 
body weight 
5–6 weeks  Onset and 
progression of 
puberty based on 
testosterone 
levels 
 
Fertility 
Testicluar 
morphology 
Normal progression of puberty 
 
Normal fertility 
 
Sertoli and leydig cell 
numbers/testes were significantly 
increased 
 
 Nutrients 2010, 2 
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2.3.2. Male Sexual Maturation, Endocrine Function and Fertility 
Most notable is the study that used twin marmoset monkeys [39] as it prompted many European 
countries to minimize the use of SBIF [52]. Importantly, unlike other studies, the marmoset monkeys 
were directly fed SBIF. In this study one twin was fed SBIF and the other was fed with cow’s milk 
formula beginning from day four or five of life. Of the twin pair, the marmoset fed SBIF, had a 
reduction in serum testosterone of 53–70% compared to its twin fed cow’s milk formula at 35–45 days 
of age [39]. Additionally, males fed cow’s milk formula had serum testosterone levels that are typical 
of the ―neonatal testosterone rise‖ observed in human male neonates whereas the SBIF group had 
consistently reduced testosterone levels. At the end of the formula feeding an increased number of 
leydig cells were reported and may indicate compensation or adjustment for leydig failure. Of note is 
the fact that monkeys in this study were exposed to 1.6–3.5 mg isoflavones/kg body weight, which is 
less than half the level of exposure compared to a human infant consuming SBIF [14]. In a later study 
however,  using  the  same  subject  group  and  feeding  protocol  normal  fertility  and  progression  of 
puberty was demonstrated [40]. Moreover, isoflavone metabolism in marmosets compared to human 
infants may be markedly different. A study in cynalogous monkeys demonstrated a markedly higher 
conversion of daidzein to equol, a more estrogenic isoflavone metabolite, than in human infants [49]. It 
is speculated that marmosets would also have a high rate of conversion from daidzein to equol. 
There was no difference in testes weight in the preliminary results of a study examining SBIF 
consumption and reproductive health in neonatal pigs, which metabolize isoflavones in a similar way 
to  human  infants  [52].  It  should  be  noted  however,  that  the  sample  size  was  relatively  small, 
n = 4/group  and  these  measurements  were  taken  at  postnatal  day  21,  prior  to  sexual  maturity. 
Furthermore, normal testes weight does not provide confirmation for normal testicular development 
and multiple measures, as discussed in Table 2, should be used to determine if disruption in sexual 
maturation or endocrine function has occurred.  
Based on the data gathered from rodent studies, there appears to be no effect of soy isoflavones on 
sexual  maturity  in  males.  Preputial  separation,  fertility,  sperm  count  and  testosterone  levels  were 
unaffected by soy isoflavone treatment at oral doses of 100 mg genistein/kg body weight. Depressed 
plasma FSH has also been reported after genistein treatment (subcutaneous injection of 4 mg/kg body 
weight) [38] yet these results contrasted with those reported by others who observed no changes in FSH, 
LH, or testosterone after using a comparable dose of genistein when it was administered orally [21]. 
3. Conclusions and Future Directions 
The biological effects of soy isoflavone exposure as a result of SBIF consumption are controversial 
and inconclusive. In summary, only one retrospective study has reported effects of feeding SBIF on 
health outcomes at adulthood and few studies have examined infant health after exposure to SBIF. 
While studies using a variety of animal models report negative effects of soy isoflavones exposure 
during development, it is unclear whether these data can be extrapolated to human infants. These 
studies do however suggest that further investigation of long term biological effects of early exposure 
to isoflavones is warranted. We feel that both studies in humans and using appropriate animal models 
are needed. Table 7 outlines various aspects of reproductive development that would be useful to Nutrients 2010, 2  
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measure  in  either  humans  or  using  animal  models.  Together,  the  findings  from  such  studies  will 
provide  a  more  comprehensive  understanding  of  the  biological  effects  of  isoflavones  in  SBIF  on 
reproductive health. 
Table 7. Future directions for human studies or using animal models. 
Outcomes to Measure in Human Subjects  Outcomes to Measure in Animals 
Prospective Cohort  
  Sexual maturity 
  Reproductive organ morphology, development 
and function 
  Serum hormone levels 
  Fertility 
  Testicular, prostate, ovarian, uterine cancer 
  Offspring characteristics (birth weight, 
sex ratio) 
Retrospective Cohort 
  Serum hormone levels 
  Fertility  
  Reproductive organ morphology and function  
  Testicular, prostate, ovarian, uterine cancer  
  Offspring characteristics: (birth weight, 
sex ratio) 
Mechanism of Endocrine Disruption  
  Hormone-specific effects on tissues  
  Altered hormone receptor expression 
and/or activity  
  Changes in gene expression 
  Organ weight and histopathology  
  Serum hormones at various life stages  
  Transgenerational effects  
Potential Outcomes Altered by Endocrine 
Disruption 
  Sexual maturity  
  Fertility  
  Testicular, prostate, ovarian, uterine 
cancer  
  Offspring characteristics 
3.1. Future Directions for Human Studies 
Both retrospective and prospective studies are needed to determine how SBIF may be affecting 
human  reproductive  health.  Prospective  studies  that  monitor  infants  who  are  currently  consuming 
SBIF, for abnormalities in reproductive organ development, such as the Beginnings Study [43], are 
needed. Prospective studies should focus not only on reproductive organ size, external genitalia and 
morphology, but also monitor for differences in pubertal onset and hormonal status. Compensated 
leydig cell failure/adjustment should also be measured in male infants. As demonstrated by [41] there 
are several techniques that are useful in order to physically examine the development of estrogen 
responsive tissues in infants. For example, breast bud diameter and vaginal cell specimens are useful 
outcomes to determine if estrogenization occurs [41]. It is suggested that vaginal cells be collected 
for >6 months and that specimens should be collected every one to two weeks for the first one to two 
months [41]. Vaginal bleeding and milk secretions, although rare, could also be documented. In males, 
the use of the urocytogram [53], which examines the hormonal responsiveness of urethral cells, could 
be assessed. Investigation to adult life is crucial since the impact of consuming SBIF may not be 
evident until adulthood. Although one retrospective study has been previously conducted [16] there is 
a need to increase the number of reproductive health outcomes measured. Performing ultrasounds, 
such as in the Beginnings Study, may be useful for identifying abnormalities in reproductive organs 
such as the occurrence of polycystic ovaries in women. Serum hormones in post-pubescent females 
should  also  be  taken  at  specific  time  points  in  the  menstrual  cycle  to  obtain  a  quantifiable 
characterization of the menstrual cycle. This may more accurately reflect menstrual abnormalities, Nutrients 2010, 2  
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rather than using self reports alone. Sperm counts and sperm characteristics should also be measured in 
adult males in order to determine function of the male reproductive system. Fertility should be closely 
examined in this population as well since abnormalities in the reproductive system of both males and 
females  do  not  necessarily  compromise  fertility.  Because  animal  studies  have  shown  a  higher 
incidence of cancer in animals consuming high levels of soy isoflavones [34], cancer screening should 
be considered for adults who have consumed SBIF in infancy. As well, offspring of those who have 
consumed SBIF should be monitored for differences in growth and development. Many individuals in 
North  America  have  consumed  SBIF  as  infants,  and  so  the  potential  to  more  extensively  assess 
reproductive health is possible. 
3.2. Future Directions for Animal Studies 
Because sexual maturation is similar across species [54], animal models still provide a practical 
design  for  studying  endocrine  function.  Numerous  endocrine-mediated  events  involved  in  this 
progression in the rat for example, are comparable to other mammalian species such as humans [50]. 
In both humans [55] and rodents [56], pubertal onset is associated with similar physiological changes 
such  as  the  attainment  of  a  body  mass,  chronic  inflammatory  states,  thyroid  disease,  and  growth 
hormone  deficiency.  The  control  of  gonadotropin  releasing  hormone  (GnRH),  the  release  of 
gonadotropins from the pituitary, and the steroid positive and negative feedback controls are fairly 
consistent across mammalian species [57]. Due to these species related similarities, the animal model 
may  provide  mechanistic  support  for  investigations  in  humans.  By  demonstrating  potential 
consequences of consuming soy isoflavones, such as increasing the number of MOFs or compromising 
embryo implantation, a better understanding of the potential impact of soy isoflavones is achieved. 
Additionally, by determining how soy isoflavones modulate gene expression and hormone receptor 
activity,  potential biological effects  may  be predicted. There are various  outcomes that cannot  be 
measured in humans such as organ weight and histology. Such outcomes, which may be markers of 
higher  rates  of  uterine  cancer,  primarily  serve  to  guide  the  direction  of  soy  isoflavone  and  SBIF 
research.  Other  environmental  estrogens,  such  as  diethlystillbesterol  are  known  to  cause  harmful 
transgenerational effects [58,59] and there has been concern that soy isoflavones may act in a similar 
way. Animal models allow for controlled and time efficient transgenerational data to be collected.  
What would an ideal animal model be? 
A mouse model could be refined to more closely characterize the human scenario. Ideally, the 
animal would be exposed orally, in order to ensure that first pass metabolism in the gut is occurring. 
As well, exposure should take place more than once per day, if technically possible, in order to mimic 
the  multiple  feedings  that  an  infant  would  receive.  Exposure  should  only  take  place  during  early 
postnatal development starting at the first day of life and during suckling, although the duration during 
suckling requires further study. Transgenerational studies, in order to characterize the offspring, are 
easily performed by breeding the treated animals to known controls and should also be conducted. 
Characterizing the ideal animal model for studying the effects of isoflavones in SBIF on human infants 
is an ongoing area of investigation. Nutrients 2010, 2  
 
 
1183 
Acknowledgements 
The authors wish to acknowledge funding to W. Ward from the Canadian Institutes for Health 
Research  (reference  #89941)  and  a  Future  Leader  Award  from  the  International  Life  Sciences 
Foundation, North America, that has allowed the authors to investigate how early exposure to soy 
isoflavones programs bone metabolism and modulates reproductive outcomes at adulthood using the 
CD-1 mouse model. 
References  
1.  Merritt, R.J.; Jenks, B.H. Safety of soy-based infant formulas containing isoflavones: The clinical 
evidence. J. Nutr. 2004, 134 (5), 1220S-1224S. 
2.  Henley, E.C.; Kuster, J.M. Protein quality evaluation by protein digestibility-corrected amino acid 
scoring. Food Technol. 1994, 48, 74-77. 
3.  Newberry,  R.E.  The  Infant  Formula  Act  of  1980.  J.  Assoc.  Off.  Anal.  Chem.  1982,  65  (6),  
1472-1473. 
4.  Centre for Disease Control and Prevention. Breastfeeding Among U.S. Children Born 1999–2007, 
CDC National Immunization Survey 2010. Available online: http://www.cdc.gov/breastfeeding/ 
data/NIS_data/ (accessed on 5 April 2010). 
5.  Canadian Paediatric Society, Dietitians of Canada and Health Canada. Statement of joint working 
group: Nutrition for healthy term infants, 1998. Available online: http://www.hc-sc.gc.ca/fn-an/ 
pubs/infant-nourrisson/nut_infant_nourrisson_term-eng.php (accessed on 5 April 2010). 
6.  American  Academy  of  Pediatrics  Committee  on  Nutrition.  Soy  protein-based  formulas: 
Recommendations for use in infant feeding. Pediatrics 1998, 101, 148-153. 
7.  UK Department of Health. Advice on Soya-Based Infant Formula; Press Release No. 96/244; 
Committee on the Toxicity of Chemicals in Food, Consumer Products, and the Environment: 
London, UK, 1996. 
8.  Australian College of Pediatrics. Positition statement: Soy protein formula. J. Paediatr. Child 
Health 1998, 34, 318-319. 
9.  Setchell, K.D.; Zimmer-Nechemias, L.; Cai, J.; Heubi, J.E. Isoflavone content of infant formulas 
and the metabolic fate of these phytoestrogens in early life. Am. J. Clin. Nutr. 1998, 68 (6), 
1453S-1461S. 
10.  Leclercq,  G.;  Heuson,  J.C.  Physiological  and  pharmacological  effects  of  estrogens  in  breast 
cancer. Biochim. Biophys. Acta 1979, 560 (4), 427-455. 
11.  Setchell, K.D. Phytoestrogens: The biochemistry, physiology, and implications for human health 
of soy isoflavones. Am. J. Clin. Nutr. 1998, 68 (6), 1333S-1346S. 
12.  Yan,  G.R.;  Xiao,  C.L.;  He,  G.W.;  Yin,  X.F.;  Chen,  N.P.;  Cao,  Y.;  He,  Q.Y.  Global 
phosphoproteomic effects of natural tyrosine kinase inhibitor, genistein, on signaling pathways. 
Proteomics 2010, 10 (5), 976-986. 
13.  Zhang, E.J.; Ng, K.M.; Luo, K.Q. Extraction and purification of isoflavones from soybeans and 
characterization of their estrogenic activities. J. Agric. Food. Chem. 2007, 55 (17), 6940-6950. Nutrients 2010, 2  
 
 
1184 
14.  Setchell,  K.D.;  Zimmer-Nechemias,  L.;  Cai,  J.;  Heubi,  J.E.  Exposure  of  infants  to 
phyto-oestrogens from soy-based infant formula. Lancet 1997, 350 (9070), 23-27. 
15.  Somekawa,Y.; Chiguchi, M.; Ishibashi,T.; Aso,T. Soy intake related to menopausal symptoms, 
serum lipids, and bone mineral density in postmenopausal Japanese women. Obstet. Gynecol. 
2001, 97 (1), 109-115. 
16.  Strom,  B.L.;  Schinnar,  R.;  Ziegler,  E.E.;  Barnhart,  K.T.;  Sammel,  M.D.;  Macones,  G.A.; 
Stallings,  V.A.;  Drulis,  J.M.;  Nelson,  S.E.;  Hanson,  S.A.  Exposure  to  soy-based  formula  in 
infancy  and  endocrinological  and  reproductive  outcomes  in  young  adulthood.  JAMA  2001, 
286 (7), 807-814. 
17.  Fontenele,  E.G.;  Martins,  M.R.;  Quidute,  A.R.;  Montenegro,  R.M.,  Jr.  Environmental 
contaminants and endocrine disruptors. Arq. Bras. Endocrinol. Metabol. 2010, 54 (1), 6-16. 
18.  Gu, L.; House, S.E.; Prior, R.L.; Fang, N.; Ronis, M.J.; Clarkson, T.B.; Wilson, M.E.; Badger, T.M. 
Metabolic phenotype of isoflavones differ among female rats, pigs, monkeys, and women. J. Nutr. 
2006, 136 (5), 1215-1221. 
19.  Jefferson, W.N.; Doerge, D.; Padilla-Banks, E.; Woodling, K.A.; Kissling, G.E.; Newbold, R. 
Oral  exposure  to  genistin,  the  glycosylated  form  of  genistein,  during  neonatal  life  adversely 
affects the female reproductive system. Environ. Health Perspect. 2009, 117 (12), 1883-1889. 
20.  Kaludjerovic,  J.;  Ward,  W.E.  Neonatal  exposure  to  daidzein,  genistein,  or  the  combination 
modulates bone development in female CD-1 mice. J. Nutr. 2009, 139 (3), 467-473. 
21.  Lewis, R.W.; Brooks, N.; Milburn, G.M.; Soames, A.; Stone, S.; Hall, M.; Ashby, J. The effects 
of the phytoestrogen genistein on the postnatal development of the rat. Toxicol. Sci. 2003, 71 (1), 
74-83. 
22.  Cimafranca, M.A.; Davila, J.; Ekman, G.C.; Andrews, R.N.; Neese, S.L.; Peretz, J.; Woodling, 
K.A.; Helferich, W.G.; Sarkar, J.; Flaws, J.A.; Schantz, S.L.; Doerge, D.R.; Cooke, P.S. Acute 
and chronic effects of oral genistein administration in neonatal mice. Biol. Reprod. 2010, 83 (1), 
114-121. 
23.  Doerge,  D.R.;  Twaddle,  N.C.;  Banks,  E.P.;  Jefferson,  W.N.;  Newbold,  R.R.  Pharmacokinetic 
analysis in serum of genistein administered subcutaneously to neonatal mice. Cancer Lett. 2002, 
184 (1), 21-27. 
24.  Barrett, J.R. Soy and children’s health: A formula for trouble. Environ. Health Perspect. 2002, 
110 (6), A294-A296. 
25  Woods,  H.F.  Committee  on  Toxicity  of  Chemicals  in  Food,  Consumer  Products  and  the 
Environment:  Phytoestrogens  and  Health;  COT  Report  No.  FSA/0826/0503;  Food  Standards 
Agency: London, UK, 2003; pp. 357-360. 
26.  National  Toxicology  Program  (NTP);  Center  for  the  Evaluation  of  Risks  to  to  Human 
Reproduction (CERHR). Updated Evaluation of Soy Infant Formula: Final Expert Panel Report; 
Federal Register Report No. 53508; National Institutes of Health: Bethesda, MD, USA, 2010. 
27.  National  Toxicology  Program  (NTP);  Center  for  the  Evaluation  of  Risks  to  to  Human 
Reproduction (CERHR). Final CERHR Expert Panel Report on Soy Formula; Federal Register 
Report No. 65537; National Institutes of Health: Bethesda, MD, USA, 2006. Nutrients 2010, 2  
 
 
1185 
28.  Jefferson, W.N.; Padilla-Banks, E.; Clark, G.; Newbold, R.R. Assessing estrogenic activity of 
phytochemicals  using  transcriptional  activation  and  immature  mouse  uterotrophic  responses.  
J. Chromatogr. B 2002, 777 (1-2), 179-189. 
29.  Jefferson, W.N.; Couse, J.F.; Padilla-Banks, E.; Korach, K.S.; Newbold, R.R. Neonatal exposure 
to  genistein  induces  estrogen  receptor  (ER)alpha  expression  and  multioocyte  follicles  in  the 
maturing mouse ovary: Evidence for ERbeta-mediated and nonestrogenic actions. Biol. Reprod. 
2002, 67 (4), 1285-1296. 
30.  Padilla-Banks,  E.;  Jefferson,  W.N.;  Newbold,  R.R.  Neonatal  exposure  to  the  phytoestrogen 
genistein alters mammary gland growth and developmental programming of hormone receptor 
levels. Endocrinology 2006, 147 (10), 4871-4882. 
31.  Jefferson, W.N.; Padilla-Banks, E.; Newbold, R.R. Adverse effects on female development and 
reproduction  in  CD-1  mice  following  neonatal  exposure  to  the  phytoestrogen  genistein  at 
environmentally relevant doses. Biol. Reprod. 2005, 73 (4), 798-806. 
32.  Nagao, T.; Yoshimura, S.; Saito, Y.; Nakagomi, M.; Usumi, K.; Ono, H. Reproductive effects in 
male and female rats of neonatal exposure to genistein. Reprod. Toxicol. 2001, 15 (4), 399-411. 
33.  Jefferson, W.; Newbold, R.; Padilla-Banks, E.; Pepling, M. Neonatal genistein treatment alters 
ovarian differentiation in the mouse: Inhibition of oocyte nest breakdown and increased oocyte 
survival. Biol. Reprod. 2006, 74 (1), 161-168. 
34.  Newbold, R.R.; Banks, E.P.; Bullock, B.; Jefferson, W.N. Uterine adenocarcinoma in mice treated 
neonatally with genistein. Cancer Res. 2001, 61 (11), 4325-4328. 
35.  Jefferson, W.N.; Padilla-Banks, E.; Goulding, E.H.; Lao, S.P.; Newbold, R.R.; Williams, C.J. 
Neonatal exposure to genistein disrupts ability of female mouse reproductive tract to support 
preimplantation embryo development and implantation. Biol. Reprod. 2009, 80 (3), 425-431. 
36.  Kouki,  T.;  Kishitake, M.;  Okamoto, M.; Oosuka, I.; Takebe, M.; Yamanouchi,  K. Effects of 
neonatal treatment with phytoestrogens, genistein and daidzein, on sex difference in female rat 
brain function: Estrous cycle and lordosis. Horm. Behav. 2003, 44 (2), 140-145. 
37.  Lamartiniere, C.A.; Zhang, J.X.; Cotroneo, M.S. Genistein studies in rats: Potential for breast 
cancer prevention and reproductive and developmental toxicity. Am. J. Clin. Nutr. 1998, 68 (6), 
1400S-1405S. 
38.  Atanassova, N.; McKinnell, C.; Turner, K.J.; Walker, M.; Fisher, J.S.; Morley, M.; Millar, M.R.; 
Groome, N.P.; Sharpe, R.M. Comparative effects of neonatal exposure of male rats to potent and 
weak (environmental) estrogens on spermatogenesis at puberty and the relationship to adult testis 
size and fertility: Evidence for stimulatory effects of low estrogen levels. Endocrinology 2000, 
141 (10), 3898-3907. 
39.  Sharpe, R.M.; Martin, B.; Morris, K.; Greig, I.; McKinnell, C.; McNeilly, A.S.; Walker, M. Infant 
feeding with soy formula milk: Effects on the testis and on blood testosterone levels in marmoset 
monkeys during the period of neonatal testicular activity. Hum. Reprod. 2002, 17 (7), 1692-1703. 
40.  Tan, K.A.; Walker, M.; Morris, K.; Greig, I.; Mason, J.I.; Sharpe, R.M. Infant feeding with soy 
formula milk: Effects on puberty progression, reproductive function and testicular cell numbers in 
marmoset monkeys in adulthood. Hum. Reprod. 2006, 21 (4), 896-904. Nutrients 2010, 2  
 
 
1186 
41.  Bernbaum,  J.C.;  Umbach,  D.M.;  Ragan,  N.B.;  Ballard,  J.L.;  Archer,  J.I.;  Schmidt-Davis,  H.; 
Rogan,  W.J.  Pilot  studies  of  estrogen-related  physical  findings  in  infants.  Environ.  Health 
Perspect. 2008, 116 (3), 416-420. 
42.  Zung, A.; Glaser, T.; Kerem, Z.; Zadik, Z. Breast development in the first 2 years of life: An 
association with soy-based infant formulas. J. Pediatr. Gastroenterol. Nutr. 2008, 46 (2), 191-195. 
43.  Gilchrist, J.M.; Moore, M.B.; Andres, A.; Estroff, J.A.; Badger, T.M. Ultrasonographic patterns 
of reproductive organs in infants fed soy formula: comparisons to infants fed breast milk and milk 
formula. J. Pediatr. 2010, 156 (2), 215-220. 
44.  Russo,  I.H.;  Russo,  J.  Developmental  stage  of  the  rat  mammary  gland  as  determinant  of  its 
susceptibility to 7,12-dimethylbenz[a]anthracene. J. Natl. Cancer Inst. 1978, 61 (6), 1439-1449. 
45.  Lamartiniere, C.A. Protection against breast cancer with genistein: A component of soy. Am. J. 
Clin. Nutr. 2000, 71 (6), 1705S-1707S; discussion 1708S-1709S. 
46.  Grubbs,  C.J.;  Farnell,  D.R.;  Hill,  D.L.;  McDonough,  K.C.  Chemoprevention  of  
N-nitroso-N-methylurea-induced mammary cancers by pretreatment with 17 beta-estradiol and 
progesterone. J. Natl. Cancer Inst. 1985, 74 (4), 927-931. 
47.  Moller,  F.J.;  Diel,  P.;  Zierau,  O.;  Hertrampf,  T.;  Maass,  J.;  Vollmer,  G.  Long-term  dietary 
isoflavone exposure enhances estrogen sensitivity of rat uterine responsiveness mediated through 
estrogen receptor alpha. Toxicol. Lett. 2010, 196, 142-153. 
48.  Varayoud, J.; Ramos, J.G.; Bosquiazzo, V.L.; Munoz-de-Toro, M.; Luque, E.H. Developmental 
exposure  to  Bisphenol  a  impairs  the  uterine  response  to  ovarian  steroids  in  the  adult. 
Endocrinology 2008, 149 (11), 5848-5860. 
49.  Freni-Titulaer, L.W.; Cordero, J.F.; Haddock, L.; Lebron, G.; Martinez, R.; Mills, J.L. Premature 
thelarche in Puerto Rico. A search for environmental factors. Am. J. Dis. Child. 1986, 140 (12), 
1263-1267. 
50.  Iguchi, T.; Fukazawa, Y.; Uesugi, Y.; Takasugi, N. Polyovular follicles in mouse ovaries exposed 
neonatally to diethylstilbestrol in vivo and in vitro. Biol. Reprod. 1990, 43 (3), 478-484. 
51.  Hillisch, A.; Peters, O.; Kosemund, D.; Muller, G.; Walter, A.; Schneider, B.; Reddersen, G.; 
Elger, W.; Fritzemeier, K.H. Dissecting physiological roles of estrogen receptor alpha and beta 
with  potent  selective  ligands  from  structure-based  design.  Mol.  Endocrinol.  2004,  18  (7),  
1599-1609. 
52.  Badger, T.M.; Gilchrist, J.M.; Pivik, R.T.; Andres, A.; Shankar, K.; Chen, J.R.; Ronis, M.J. The 
health implications of soy infant formula. Am. J. Clin. Nutr. 2009, 89 (5), 1668S-1672S. 
53.  Preeyasombat,  C.;  Kenny,  F.M.  Urocytograms  in  normal  children  and  various  abnormal 
conditions. Pediatrics 1966, 38 (3), 436-443. 
54.  Stoker, T.E.; Parks, L.G.; Gray, L.E.; Cooper, R.L. Endocrine-disrupting chemicals: Prepubertal 
exposures and effects on sexual maturation and thyroid function in the male rat. A focus on the 
EDSTAC recommendations. Endocrine Disrupter Screening and Testing Advisory Committee. 
Crit. Rev. Toxicol. 2000, 30 (2), 197-252. 
55.  Frisch, R.E.; Revelle, R. Height and weight at menarche and a hypothesis of critical body weights 
and adolescent events. Science 1970, 169 (943), 397-399. 
56.  Frisch, R.E.; Hegsted, D.M.; Yoshinaga, K. Body weight and food intake at early estrus of rats on 
a high-fat diet. Proc. Natl. Acad. Sci. USA 1975, 72 (10), 4172-4176. Nutrients 2010, 2  
 
 
1187 
57.  Ojeda, S.R.; Urbanski, H.F. Puberty in the Rat, 2nd ed.; Raven Press: New York, NY, USA, 1994. 
58.  Newbold, R.R.; Padilla-Banks, E.; Jefferson, W.N. Adverse effects of the model environmental 
estrogen  diethylstilbestrol  are  transmitted  to  subsequent  generations.  Endocrinology  2006, 
147 (6), S11-S17. 
59.  Titus-Ernstoff, L.; Troisi, R.; Hatch, E.E.; Wise, L.A.; Palmer, J.; Hyer, M.; Kaufman, R.; Adam, 
E.; Strohsnitter, W.; Noller, K.; Herbst, A.L.; Gibson-Chambers, J.; Hartge, P.; Hoover, R.N. 
Menstrual and reproductive characteristics of women whose mothers were exposed in utero to 
diethylstilbestrol (DES). Int. J. Epidemiol. 2006, 35 (4), 862-868. 
© 2010  by  the authors; licensee  MDPI, Basel, Switzerland. This article is  an open access article 
distributed  under  the  terms  and  conditions  of  the  Creative  Commons  Attribution  license 
(http://creativecommons.org/licenses/by/3.0/). 